Stericycle Future Growth

Future criteria checks 3/6

Stericycle wird ein jährliches Wachstum der Erträge und Einnahmen um 56.9% bzw. 3.4% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich grow um 57.2% pro Jahr steigen. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 10% betragen.

Key information

38.2%

Earnings growth rate

38.8%

EPS growth rate

Commercial Services earnings growth	15.0%
Revenue growth rate	4.0%
Future return on equity	10.9%
Analyst coverage	Good
Last updated	20 Mar 2024

Recent future growth updates

Recent updates

We Think Stericycle (NASDAQ:SRCL) Can Stay On Top Of Its Debt

Apr 02

Is There An Opportunity With Stericycle, Inc.'s (NASDAQ:SRCL) 47% Undervaluation?

Mar 07

Stericycle: Earnings Beat And Above-Expectations Guidance Reinforce My Buy Rating

Mar 03

Stericycle, Inc. (NASDAQ:SRCL) Shares Could Be 44% Below Their Intrinsic Value Estimate

Dec 01

Stericycle (NASDAQ:SRCL) Hasn't Managed To Accelerate Its Returns

Oct 26

Here's Why Stericycle (NASDAQ:SRCL) Can Manage Its Debt Responsibly

Sep 13

Is There An Opportunity With Stericycle, Inc.'s (NASDAQ:SRCL) 37% Undervaluation?

Jul 19

Stericycle (NASDAQ:SRCL) Will Be Hoping To Turn Its Returns On Capital Around

Jul 03

Stericycle (NASDAQ:SRCL) Seems To Use Debt Quite Sensibly

Jun 15

At US$42.07, Is Stericycle, Inc. (NASDAQ:SRCL) Worth Looking At Closely?

Apr 24

An Intrinsic Calculation For Stericycle, Inc. (NASDAQ:SRCL) Suggests It's 40% Undervalued

Apr 04

These Return Metrics Don't Make Stericycle (NASDAQ:SRCL) Look Too Strong

Mar 14

We Think Stericycle (NASDAQ:SRCL) Is Taking Some Risk With Its Debt

Feb 24

What Is Stericycle, Inc.'s (NASDAQ:SRCL) Share Price Doing?

Jan 16

An Intrinsic Calculation For Stericycle, Inc. (NASDAQ:SRCL) Suggests It's 37% Undervalued

Dec 23

These Return Metrics Don't Make Stericycle (NASDAQ:SRCL) Look Too Strong

Dec 02

Stericycle's (NASDAQ:SRCL) Conservative Accounting Might Explain Soft Earnings

Nov 10

We Think Stericycle (NASDAQ:SRCL) Is Taking Some Risk With Its Debt

Oct 11

Stericycle: Muted Outlook, Fair Valuations

Aug 30

Stericycle Q2 2022 Earnings Preview

Aug 04

Be Wary Of Stericycle (NASDAQ:SRCL) And Its Returns On Capital

Aug 02

Is Stericycle (NASDAQ:SRCL) A Risky Investment?

Jun 28

Stericycle: The Risks Outweigh The Reward

Jun 03

Capital Allocation Trends At Stericycle (NASDAQ:SRCL) Aren't Ideal

Apr 25

Is Stericycle, Inc. (NASDAQ:SRCL) Trading At A 40% Discount?

Mar 29

Stericycle: A Neutral View

Oct 22

Stericycle: A Successful Turnaround Is Likely

Aug 08

Stericycle Q1 2021 Earnings Preview

Apr 28

Stericycle: Future Profitability Influenced By Divestments And ERP Implementation

Feb 04

Stericycle divests global product business

Dec 02

Stericycle Continues Its Mediocre Performance

Nov 18

Stericycle launches $400M senior notes offering

Nov 09

Stericycle up 11% on beating Q3 estimates, and improved margins

Nov 05

Stericycle Q3 2020 Earnings Preview

Nov 04

Earnings and Revenue Growth Forecasts

NasdaqGS:SRCL - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	2,987	311	360	471	2
12/31/2025	2,832	185	293	417	7
12/31/2024	2,730	124	253	370	7
12/31/2023	2,659	-21	112	243	N/A
9/30/2023	2,678	-4	222	350	N/A
6/30/2023	2,715	22	248	374	N/A
3/31/2023	2,725	81	157	289	N/A
12/31/2022	2,705	56	68	200	N/A
9/30/2022	2,692	7	7	144	N/A
6/30/2022	2,650	-87	8	135	N/A
3/31/2022	2,643	-68	72	202	N/A
12/31/2021	2,647	-28	186	303	N/A
9/30/2021	2,646	38	257	367	N/A
6/30/2021	2,633	23	368	473	N/A
3/31/2021	2,559	-11	406	511	N/A
12/31/2020	2,676	-57	411	530	N/A
9/30/2020	2,820	-325	284	412	N/A
6/30/2020	3,016	-303	224	384	N/A
3/31/2020	3,264	-329	126	294	N/A
12/31/2019	3,309	-347	54	248	N/A
9/30/2019	3,362	-446	82	277	N/A
6/30/2019	3,384	-369	-169	6	N/A
3/31/2019	3,421	-312	-77	92	N/A
12/31/2018	3,486	-253	35	166	N/A
9/30/2018	3,521	148	58	207	N/A
6/30/2018	3,549	166	357	501	N/A
3/31/2018	3,583	-9	312	451	N/A
12/31/2017	3,581	23	366	509	N/A
9/30/2017	3,599	-47	N/A	535	N/A
6/30/2017	3,607	-21	N/A	554	N/A
3/31/2017	3,581	165	N/A	572	N/A
12/31/2016	3,562	178	N/A	561	N/A
9/30/2016	3,544	236	N/A	515	N/A
6/30/2016	3,373	244	N/A	457	N/A
3/31/2016	3,197	295	N/A	415	N/A
12/31/2015	2,986	257	N/A	386	N/A
9/30/2015	2,775	269	N/A	397	N/A
6/30/2015	2,724	282	N/A	389	N/A
3/31/2015	2,649	276	N/A	435	N/A
12/31/2014	2,556	326	N/A	449	N/A
9/30/2014	2,447	322	N/A	414	N/A
6/30/2014	2,313	320	N/A	467	N/A
3/31/2014	2,199	316	N/A	453	N/A
12/31/2013	2,143	311	N/A	405	N/A
9/30/2013	2,079	303	N/A	446	N/A
6/30/2013	2,024	288	N/A	375	N/A

Analyst Future Growth Forecasts

Einkommen vs. Sparrate: SRCL wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (2.3%).

Ertrag vs. Markt: SRCL wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.

Hohe Wachstumserträge: SRCL wird voraussichtlich in den nächsten 3 Jahren rentabel werden.

Einnahmen vs. Markt: SRCLDie Einnahmen des Unternehmens (3.4% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (8.1% pro Jahr).

Hohe Wachstumseinnahmen: SRCLDie Einnahmen des Unternehmens (3.4% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Earnings per Share Growth Forecasts

Future Return on Equity

Künftige Eigenkapitalrendite: SRCLDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (10%).

Discover growth companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Stericycle Future Growth

Future criteria checks 3/6

Key information

Recent future growth updates

Price target increased by 15% to US$61.83

Consensus EPS estimates fall by 10%

Consensus EPS estimates fall by 49%

Consensus EPS estimates fall by 40%

Price target decreased by 8.5% to US$62.00

Price target decreased to US$65.20

Recent updates

We Think Stericycle (NASDAQ:SRCL) Can Stay On Top Of Its Debt

President exercised options and sold US$615k worth of stock

President exercised options and sold US$808k worth of stock

Is There An Opportunity With Stericycle, Inc.'s (NASDAQ:SRCL) 47% Undervaluation?

Stericycle: Earnings Beat And Above-Expectations Guidance Reinforce My Buy Rating

Price target increased by 15% to US$61.83

Returns On Capital At Stericycle (NASDAQ:SRCL) Paint A Concerning Picture

Stericycle, Inc.'s (NASDAQ:SRCL) Shares May Have Run Too Fast Too Soon

We Think Stericycle (NASDAQ:SRCL) Can Stay On Top Of Its Debt

Stericycle, Inc. (NASDAQ:SRCL) Shares Could Be 44% Below Their Intrinsic Value Estimate

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Stericycle (NASDAQ:SRCL) Hasn't Managed To Accelerate Its Returns

Consensus EPS estimates fall by 10%

Here's Why Stericycle (NASDAQ:SRCL) Can Manage Its Debt Responsibly

Stericycle, Inc. Reports Impairment Changes for the Second Quarter Ended June 30, 2023

Consensus EPS estimates fall by 49%

Is There An Opportunity With Stericycle, Inc.'s (NASDAQ:SRCL) 37% Undervaluation?

Stericycle (NASDAQ:SRCL) Will Be Hoping To Turn Its Returns On Capital Around

Stericycle (NASDAQ:SRCL) Seems To Use Debt Quite Sensibly

Executive VP & Chief People Officer recently bought US$309k worth of stock

Enviri Corporation Reaches an Amicable Agreement with Stericycle, Inc

Stericycle, Inc. Approves the Election of Victoria L. Dolan as Director

Consensus EPS estimates fall by 40%

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

At US$42.07, Is Stericycle, Inc. (NASDAQ:SRCL) Worth Looking At Closely?

Executive VP exercised options and sold US$109k worth of stock

An Intrinsic Calculation For Stericycle, Inc. (NASDAQ:SRCL) Suggests It's 40% Undervalued

These Return Metrics Don't Make Stericycle (NASDAQ:SRCL) Look Too Strong

President exercised options and sold US$189k worth of stock

Director recently bought US$287k worth of stock

Price target decreased by 8.5% to US$62.00

We Think Stericycle (NASDAQ:SRCL) Is Taking Some Risk With Its Debt

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Now 20% undervalued

What Is Stericycle, Inc.'s (NASDAQ:SRCL) Share Price Doing?

An Intrinsic Calculation For Stericycle, Inc. (NASDAQ:SRCL) Suggests It's 37% Undervalued

Stericycle, Inc. Appoints Naren K. Gursahaney to the Board of Directors, Effective January 1, 2023

Infomedia Group, Inc. acquired Stericycle Communication Solutions, Inc. from Stericycle, Inc. (NasdaqGS:SRCL) for $45 million.

These Return Metrics Don't Make Stericycle (NASDAQ:SRCL) Look Too Strong

Insufficient new directors

Stericycle's (NASDAQ:SRCL) Conservative Accounting Might Explain Soft Earnings

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

We Think Stericycle (NASDAQ:SRCL) Is Taking Some Risk With Its Debt

Stericycle: Muted Outlook, Fair Valuations

Price target decreased to US$65.20

Stericycle Q2 2022 Earnings Preview

Be Wary Of Stericycle (NASDAQ:SRCL) And Its Returns On Capital

Executive VP exercised options and sold US$93k worth of stock

Is Stericycle (NASDAQ:SRCL) A Risky Investment?

Stericycle: The Risks Outweigh The Reward

Insufficient new directors

Price target decreased to US$63.67

President exercised options and sold US$62k worth of stock

First quarter 2022 earnings: EPS misses analyst expectations

Capital Allocation Trends At Stericycle (NASDAQ:SRCL) Aren't Ideal

Stericycle, Inc., Annual General Meeting, May 26, 2022

Stericycle, Inc. Announces New Safeshield™ Medical Waste Containers

High number of new directors

Is Stericycle, Inc. (NASDAQ:SRCL) Trading At A 40% Discount?

President exercised options and sold US$169k worth of stock

Senior VP & Chief Accounting Officer exercised options and sold US$51k worth of stock

Stericycle, Inc. Provides Earnings Guidance for the Full-Year 2022

Full year 2021 earnings: EPS misses analyst expectations

Consensus forecasts updated

Third quarter 2021 earnings released: US$0.72 loss per share (vs US$0.89 loss in 3Q 2020)

President exercised options and sold US$70k worth of stock

Stericycle: A Neutral View

Second quarter 2021 earnings released: EPS US$0.32 (vs US$0.049 loss in 2Q 2020)

Stericycle: A Successful Turnaround Is Likely